pvymo 27.11.2023

Laboratory of theranostics

1031

Origins and our mission

Laboratory of theranostics was established in 2022 as a joint laboratory of the 1st Faculty of Medicine, Charles University in Prague and the Institute of Organic Chemistry and Biochemistry (IOCB) of the Czech Academy of Sciences. Our mission is to try to unlock the potential of the small molecules around us and use them in cancer diagnosis and therapy. We are trying to find new molecular targets, both on cancer cells themselves and in key processes of carcinogenesis. For these targets we are trying to find, in collaboration with organic chemists (from the IOCB), substances that interact with them and use them as therapeutic tools, or new diagnostic probes. In collaboration with Institute of Macromolecuar (MCH), we are trying to improve the properties of these compounds and target them to tumor tissues.

Ongoing projects

Development of a method for the identification of membrane protein targets of biologically active compounds (GAČR 23-05642S)

In this project, we aim to uncover the molecular targets of the angiogenesis inhibitor PEDF (Pigment epithelium-derived factor) and endostatin using proximity labeling. A thorough understanding of the mechanism of action may aid the design of molecules that significantly inhibit angiogenesis and thus tumor growth.

Research study on the anti-glioma activity of synthetic analogues/nanostructures derived from natural alkaloids originating from the plants of Amaryllidaceae family

Malignant gliomas still represent a disease with a very poor prognosis. In this project, we attempt to evaluate the potential of modified natural compounds derived from plants of the Amaryllidaceae family in vitro and in vivo.

1034

Figure 1: Narciclasin (left) as one of the pharmacologically active cytostatic substances from plants of the Amaryllidaceae family (right).

Funding

Colaboration

People

Head of the laboratory: František Sedlák, M.D., Ph.D.

PhD students: Ing. Veronika Liščáková

Undergraduated students: Tomáš Palušák

Part-time technical help: RNDr. Jan Stejskal

Selected previous works

Hejdanková Z, Vaněk V, Sedlák F, Procházka J, Diederichs A, Kereïche S, Novotná B, Budešínsky M, Birkuš G, Šašková KG, Cígler P: Lipid Nanoparticles for Broad-Spectrum Nucleic Acid Delivery. Adv. Funct. Mater. 2021, 31, 2101391. IF (2020/2021) = 18,808

Fassmannová D, Sedlák F, Sedláček J, Špička I, Grantz Šašková K: Nelfinavir Inhibits the TCF11/Nrf1-Mediated Proteasome Recovery Pathway in Multiple Myeloma. Cancers (Basel). 2020 Apr 25;12(5):1065. IF (2020) = 6,639

Vorlová B, Sedlák F, Kašpárek P, Šrámková K, Malý M, Zámečník J, Šácha P, Konvalinka J.: A novel PSMA/GCPII-deficient mouse model shows enlarged seminal vesicles upon aging. Prostate. 2019 Feb;79(2):126-139. IF (2019) = 3,279

Neburková J, Sedlák F, Žáčková Suchanová J, Kostka L, Šácha P, Šubr V, Etrych T, Šimon P, Bařinková J, Kryštufek R, Španielová H, Forstová J, Konvalinka J, Cígler P: Inhibitor-GCPII Interaction: Selective and Robust System for Targeting Cancer Cells with Structurally Diverse Nanoparticles. Mol Pharm. 2018 Aug 6;15(8):2932-2945. IF (2018) = 4,65

Šlegerová J, Hájek M, Řehoř I, Sedlák F, Stursa J, Hrubý M, Cígler P.: Designing the nanobiointerface of fluorescent nanodiamonds: highly selective targeting of glioma cancer cells. Nanoscale. 2015 Jan 14;7(2):415-20 IF (2015) = 7.76

number of views: 447 author: pvymo, last modification: pvymo, 27.11.2023

Page ranking: If you think the article is not up-to-date, click here.